Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer’s Disease

Although preclinical research and observer studies on patients with atrial fibrillation concluded that direct oral anticoagulants (DOACs) can protect against dementia like Alzheimer’s disease (AD), clinical investigation towards therapeutical approval is still pending. DOACs target pathological thro...

Descripción completa

Detalles Bibliográficos
Autor principal: Grossmann, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405823/
https://www.ncbi.nlm.nih.gov/pubmed/36009437
http://dx.doi.org/10.3390/biomedicines10081890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405823/
https://www.ncbi.nlm.nih.gov/pubmed/36009437
http://dx.doi.org/10.3390/biomedicines10081890

Ejemplares similares